The investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) completed the open-label, pioneer portion of the trial.
Lexicon president and chief executive officer Dr. Arthur Sands said, "The preliminary results are very encouraging and provide a strong rationale for moving into the expansion phase of the trial."
The pioneer phase results indicate that the 400mg once daily dose of LX4211 is appropriate treatment for the expansion phase of the trial.
LX4211inhibits SGLT1 to reduce the amount of glucose that enters the bloodstream from the gastrointestinal tract and inhibits SGLT2 to enhance glucose excretion in the urine.